Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK”

419 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 419 results

Not applicableStudy completedNCT01662635
What this trial is testing

Clinicopathological Features of NSCLC Patients Associated With the Chromosome 2p (EML4-ALK)

Who this might be right for
Non Small-cell Lung Cancer
Instituto Nacional de Cancerologia de Mexico 230
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07330076
What this trial is testing

Iruplinalkib Tablets as Postoperative Adjuvant Therapy in Stage IA ALK-positive NSCLC With High-risk Factors

Who this might be right for
NSCLC
Tianjin Medical University Cancer Institute and Hospital 28
Not applicableUnknownNCT03764917
What this trial is testing

NGS Combined With RNAseq on Tumor Immune Escape in NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China 100
Testing effectiveness (Phase 2)Study completedNCT01524926
What this trial is testing

CREATE: Cross-tumoral Phase 2 With Crizotinib

Who this might be right for
Locally Advanced and/or Metastatic Anaplastic Large Cell LymphomaLocally Advanced and/or Metastatic Inflammatory Myofibroblastic TumorLocally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1+3 more
European Organisation for Research and Treatment of Cancer - EORTC 582
Not applicableNo Longer AvailableNCT03066661
What this trial is testing

Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions

Who this might be right for
Cancers With NTRK, ROS1, or ALK Gene Fusions
Hoffmann-La Roche
Testing effectiveness (Phase 2)Study completedNCT04681131
What this trial is testing

CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

Who this might be right for
Non-Small-Cell Lung Cancer
BioAtla, Inc. 85
Testing effectiveness (Phase 2)Active Not RecruitingNCT02650401
What this trial is testing

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

Who this might be right for
Solid TumorsCNS Tumors
Hoffmann-La Roche 69
Early research (Phase 1)Study completedNCT02292550
What this trial is testing

Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.

Who this might be right for
Non-small Cell Lung Cancer
Novartis Pharmaceuticals 27
Testing effectiveness (Phase 2)Active Not RecruitingNCT05491811
What this trial is testing

Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation

Who this might be right for
Non-Small Cell Lung Cancer
Sun Yat-sen University 49
Testing effectiveness (Phase 2)Looking for participantsNCT06947694
What this trial is testing

A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases

Who this might be right for
NSCLC Stage IV Without EGFR/ALK Mutation
Xinqiao Hospital of Chongqing 427
Early research (Phase 1)Study completedNCT03607188
What this trial is testing

Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 17
Not applicableStudy completedNCT03271554
What this trial is testing

Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 355
Testing effectiveness (Phase 2)UnknownNCT04056572
What this trial is testing

Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Who this might be right for
ALK-positive NSCLC
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 135
Not applicableLooking for participantsNCT05599412
What this trial is testing

Post Marketing Surveillance(PMS) Study of Lorviqua in Korea

Who this might be right for
Metastatic ALK+ Non Small Cell Lung Cancer
Pfizer 600
Early research (Phase 1)Active Not RecruitingNCT05681780
What this trial is testing

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

Who this might be right for
Non Small Cell Lung CancerStage IV Non-small Cell Lung CancerRecurrent Non Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute 13
Testing effectiveness (Phase 2)Active Not RecruitingNCT03737994
What this trial is testing

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

Who this might be right for
Lung Non-Squamous Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8+1 more
National Cancer Institute (NCI) 10
Testing effectiveness (Phase 2)Ended earlyNCT04676360
What this trial is testing

Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma

Who this might be right for
Relapsed Plasmablastic LymphomaRefractory Plasmablastic LymphomaAnaplastic Lymphoma Kinase Positive Large B-Cell Lymphoma
Jacob Soumerai, MD 10
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06779539
What this trial is testing

Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
West China Hospital 33
Testing effectiveness (Phase 2)Study completedNCT02419287
What this trial is testing

Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas

Who this might be right for
Anaplastic Large Cell Lymphoma, ALK-Positive
University of Milano Bicocca 12
Testing effectiveness (Phase 2)UnknownNCT02533700
What this trial is testing

CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL

Who this might be right for
Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedAngioimmunoblastic T Cell LymphomaALK-negative Anaplastic Large Cell Lymphoma+3 more
Shandong Provincial Hospital 106
Load More Results